Johnson & Johnson (NYSE:JNJ) Shares Sold by American Trust

American Trust decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 40,727 shares of the company’s stock after selling 4,249 shares during the quarter. American Trust’s holdings in Johnson & Johnson were worth $6,653,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Geller Advisors LLC raised its holdings in shares of Johnson & Johnson by 7.5% during the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after acquiring an additional 648 shares during the last quarter. Lincoln Capital Corp raised its holdings in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after acquiring an additional 183 shares during the last quarter. Ieq Capital LLC raised its holdings in shares of Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after acquiring an additional 6,154 shares during the last quarter. Ranch Capital Advisors Inc. raised its holdings in shares of Johnson & Johnson by 3.2% during the second quarter. Ranch Capital Advisors Inc. now owns 10,154 shares of the company’s stock valued at $1,802,000 after acquiring an additional 318 shares during the last quarter. Finally, RFG Advisory LLC raised its holdings in shares of Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after acquiring an additional 594 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on JNJ shares. SVB Leerink reduced their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Citigroup upped their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Morgan Stanley upped their price target on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. Finally, Atlantic Securities upped their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $174.73.

Johnson & Johnson Trading Down 1.1 %

JNJ opened at $152.38 on Friday. Johnson & Johnson has a 52 week low of $150.71 and a 52 week high of $186.69. The business has a fifty day simple moving average of $161.97 and a 200-day simple moving average of $167.91. The firm has a market cap of $396.84 billion, a P/E ratio of 22.61, a P/E/G ratio of 2.66 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same period last year, the business posted $2.13 earnings per share. The company’s quarterly revenue was down 4.4% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.97%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s payout ratio is currently 67.06%.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.